NovaVision, Inc.

The Company
NovaVision, Inc., headquartered in Boca Raton, Fla., develops and provides scientifically-based, innovative medical devices and comprehensive solutions to restore the vision of patients with neurological visual impairments. FDA-cleared in 2003, NovaVision’s Vision Restoration Therapy devices work by enhancing neuroplasticity – the brain’s ability to adapt and form new connections to compensate for injury. NovaVision’s diagnostic program maps areas where vision may be improved, and the therapy program targets and stimulates regions within the brain’s vision-processing areas.

NovaVision VRT® is based on more than 10 years of research with clinical studies published in leading journals including Nature Medicine, Neurology, and The Journal of Cognitive Neuroscience. Data from a recent retrospective study identified that more than 70 percent of patients who underwent VRT for an initial six-month treatment period showed measurable improvements in their vision.

VRT is currently offered at leading neurological, eye and rehabilitation centers nationwide.

Current Investors/Backers
NovaVision, Inc. is backed by a group of top tier investors including Chicago Growth Partners, Crossbow Ventures, Johnson & Johnson, Nor-Moseley Partners, Oakwood Medical Investors and Tullis-Dickerson & Co., Inc.

For more information on NovaVision, Inc., please visit their web site at www.novavision.com